Filings
Finds words inside filing documents. Searching Cartesian Therapeutics, Inc.'s filings · 44 documents indexed.
4 documents · 5 matches
-
RNAC Cartesian Therapeutics, Inc. 10-K 2026-03-09
Item 1A. Risk Factors
material weakness in our internal control over financial reporting. As of December 31, 2024, this material weakness has been remediated2 matches in this document -
RNAC Cartesian Therapeutics, Inc. 10-Q 2025-11-06
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
material. Therefore, our cell therapy is distinguished by its capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies. In our Phase 2b clinical trial in patients with myasthenia gravis1 match in this document -
RNAC Cartesian Therapeutics, Inc. 10-Q 2025-08-07
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
material. Therefore, our cell therapy is distinguished by its capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies. In our Phase 2b clinical trial in patients with myasthenia gravis1 match in this document -
RNAC Cartesian Therapeutics, Inc. 10-Q 2025-05-08
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
material. Therefore, our cell therapies are distinguished by their capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies. In our Phase 2b clinical trial in patients with myasthenia gravis1 match in this document
Page 1 of 1 · 4 documents